BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19605778)

  • 1. The tissue-type plasminogen activator story.
    Collen D; Lijnen HR
    Arterioscler Thromb Vasc Biol; 2009 Aug; 29(8):1151-5. PubMed ID: 19605778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator: a historical perspective and personal account.
    Collen D; Lijnen HR
    J Thromb Haemost; 2004 Apr; 2(4):541-6. PubMed ID: 15102005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential approaches for therapeutic intervention of thrombosis by fibrinolytic agents.
    Collen D
    Semin Thromb Hemost; 1988 Jan; 14(1):95-9. PubMed ID: 3127886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-type plasminogen activator.
    Lijnen HR; Collen D
    Ann Biol Clin (Paris); 1987; 45(2):198-201. PubMed ID: 2956911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant peptides in thrombolysis.
    Campbell J; Hilleman D
    Semin Thromb Hemost; 2010 Jul; 36(5):529-36. PubMed ID: 20632250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New strategies and perspectives in thrombolytic therapy].
    Bode C; Kübler W
    Internist (Berl); 1992 Apr; 33(4):258-64. PubMed ID: 1612850
    [No Abstract]   [Full Text] [Related]  

  • 9. [The fibrinolytic system and its activators].
    Seifried E
    Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolytic therapy.
    Collen D
    Thromb Haemost; 1997 Jul; 78(1):742-6. PubMed ID: 9198249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA.
    Heeremans JL; Prevost R; Bekkers ME; Los P; Emeis JJ; Kluft C; Crommelin DJ
    Thromb Haemost; 1995 Mar; 73(3):488-94. PubMed ID: 7667833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination thrombolytic and anticoagulant therapy for bilateral renal vein thrombosis in a premature infant.
    Weinschenk N; Pelidis M; Fiascone J
    Am J Perinatol; 2001 Aug; 18(5):293-7. PubMed ID: 11552182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Staphylokinase--a specific plasminogen activator].
    Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
    Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New methods accelerate the development of thrombolytic agents].
    Wiman B; Hamsten A
    Lakartidningen; 1991 Jan; 88(1-2):37, 40-1. PubMed ID: 2002712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of T-PA on thrombosis, an experimental study].
    Gu YD
    Zhonghua Wai Ke Za Zhi; 1991 Oct; 29(10):605-7, 652-3. PubMed ID: 1815902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy.
    Uesugi Y; Kawata H; Jo J; Saito Y; Tabata Y
    J Control Release; 2010 Oct; 147(2):269-77. PubMed ID: 20696194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibrinolytic system: from Petri dishes to genetic engineering.
    Verstraete M
    Thromb Haemost; 1995 Jul; 74(1):25-35. PubMed ID: 8578467
    [No Abstract]   [Full Text] [Related]  

  • 19. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
    Flight SM; Masci PP; Lavin MF; Gaffney PJ
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):417-20. PubMed ID: 16788320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thrombolytic agents].
    Nagao T
    Nihon Rinsho; 2014 Jul; 72(7):1254-7. PubMed ID: 25163317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.